FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Chronically activated leukocytes recruited to premalignant tissues functionally contribute to cancer development; however, mechanisms underlying pro- versus anti-tumor programming of neoplastic tissues by immune cells remain obscure. Using the K14-HPV16 mouse model of squamous carcinogenesis, we report that B cells and humoral immunity foster cancer development by activating Fcgamma receptors (FcgammaRs) on resident and recruited myeloid cells. Stromal accumulation of autoantibodies in premalignant skin, through their interaction with activating FcgammaRs, regulate recruitment, composition, and bioeffector functions of leukocytes in neoplastic tissue, which in turn promote neoplastic progression and subsequent carcinoma development. These findings support a model in which B cells, humoral immunity, and activating FcgammaRs are required for establishing chronic inflammatory programs that promote de novo carcinogenesis.

[1]  L. Yao,et al.  Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. , 2004, The Journal of clinical investigation.

[2]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[3]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[4]  V. D’Agati,et al.  FcR-Bearing Myeloid Cells Are Responsible for Triggering Murine Lupus Nephritis1 , 2006, The Journal of Immunology.

[5]  Christopher A. Lazarski,et al.  Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein , 2000, The Journal of experimental medicine.

[6]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[7]  P. Conti,et al.  Mast cells: the Jekyll and Hyde of tumor growth. , 2004, Trends in immunology.

[8]  Hailing Lu,et al.  Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. , 2008, Journal of proteome research.

[9]  J. Köhl,et al.  Distinct Tissue Site-Specific Requirements of Mast Cells and Complement Components C3/C5a Receptor in IgG Immune Complex-Induced Injury of Skin and Lung1 , 2001, The Journal of Immunology.

[10]  D. Hanahan,et al.  Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice , 1994, Journal of virology.

[11]  D. Hanahan,et al.  Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. , 1996, The American journal of pathology.

[12]  J. Ravetch,et al.  FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.

[13]  J. Nyhus,et al.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. , 1999, Neoplasia.

[14]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[15]  A. Divekar,et al.  Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells , 2005, International journal of cancer.

[16]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[17]  Andrea Falini,et al.  Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. , 2008, Cancer cell.

[18]  M. Lyon,et al.  A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. , 1982, Genetical research.

[19]  A. Sica,et al.  A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. , 2009, Blood.

[20]  K. O'Byrne,et al.  Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. , 2002, Advances in cancer research.

[21]  Feng Chen,et al.  Statistical analysis of real-time PCR data , 2006, BMC Bioinformatics.

[22]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[23]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[24]  S. Ostrand-Rosenberg,et al.  Immune surveillance: a balance between protumor and antitumor immunity. , 2008, Current opinion in genetics & development.

[25]  D. Hanahan,et al.  CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. , 2005, Cancer research.

[26]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[27]  G. Evan,et al.  Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors , 2007, Nature Medicine.

[28]  D. Hoelzer,et al.  Novel antibody-based therapy for acute lymphoblastic leukaemia. , 2006, Best practice & research. Clinical haematology.

[29]  D. Hanahan,et al.  Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. , 1996, Oncogene.

[30]  F. Alt,et al.  Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. , 1993, International immunology.

[31]  J. Ravetch,et al.  FcR gamma chain deletion results in pleiotrophic effector cell defects. , 1994, Cell.

[32]  John Calvin Reed,et al.  Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. , 2009, Blood.

[33]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[34]  J. Nyhus,et al.  B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion , 2000, Cancer Immunology, Immunotherapy.

[35]  J. Pollard,et al.  Macrophages define the invasive microenvironment in breast cancer , 2008, Journal of leukocyte biology.

[36]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[37]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.

[38]  L. Coussens,et al.  Early neoplastic progression is complement independent. , 2004, Neoplasia.

[39]  D. Keskin,et al.  A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.

[40]  T. Halstensen,et al.  The B-cell system in inflammatory bowel disease. , 2006, Advances in experimental medicine and biology.

[41]  L. Coussens,et al.  Analysis of immune cell infiltrates during squamous carcinoma development. , 2006, The journal of investigative dermatology. Symposium proceedings.

[42]  T. Takai.  Fc Receptors and Their Role in Immune Regulation and Autoimmunity , 2005, Journal of Clinical Immunology.

[43]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.